Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer-Reference-Cited by-同舟云学术

Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer

Published:2022-12 Issue: Volume:177 Page:40-45
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Visani Luca,Livi Lorenzo,Ratosa Ivica,Orazem Miha,Ribnikar Domen,Saieva Calogero,Becherini Carlotta,Salvestrini Viola,Scoccimarro Erika,Valzano Marianna,Cerbai Cecilia,Desideri Isacco,Bernini Marco,Orzalesi Lorenzo,Nori Jacopo,Bianchi Simonetta,Morandi Andrea,Meattini Icro

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference45 articles.

1. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

2. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016

3. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3;Slamon;J Clin Oncol,2018

4. Overall survival with palbociclib and fulvestrant in advanced breast cancer;Turner;N Engl J Med,2018

5. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial;Tripathy;Lancet Oncol,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data;Pharmaceuticals;2024-07-11

2. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023;Bulletin du Cancer;2023-11

3. Moderate adverse events and regional differences in CDK4/6 inhibitor treatment combined with palliative radiotherapy;Radiotherapy and Oncology;2023-11

4. Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis;Radiotherapy and Oncology;2023-10

5. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis;Cancer Treatment Reviews;2023-09